Antiplatelet therapy in acute coronary syndromes

@article{Grove2015AntiplateletTI,
  title={Antiplatelet therapy in acute coronary syndromes},
  author={E. Grove and M. W{\"u}rtz and Mark R Thomas and S. Kristensen},
  journal={Expert Opinion on Pharmacotherapy},
  year={2015},
  volume={16},
  pages={2133 - 2147}
}
Introduction: Coronary thrombosis is a frequent cause of death and myocardial infarction most often explained by superimposition of a platelet-rich thrombus on existing coronary artery disease. Therefore, antiplatelet drugs are essential in the treatment and secondary prevention of acute coronary syndromes (ACS) and during percutaneous coronary intervention. Several novel antiplatelet drugs are now available. Areas covered: For several years, aspirin and clopidogrel remained the cornerstone of… Expand
Combined antiplatelet therapy: still a sweeping combination in cardiology.
The Effect of Antiplatelet Medications on Innate Immune Activation
...
1
2
...

References

SHOWING 1-10 OF 118 REFERENCES
Antiplatelet therapy in patients with diabetes mellitus.
Update on oral antiplatelet therapy: principles, problems and promises.
Can we improve the efficacy of low-dose aspirin?
Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
...
1
2
3
4
5
...